Chronic active antibody-mediated rejection is a form of late rejection with a poor prognosis. To identify specific markers of this, we analyzed several microarray studies in the literature and performed mRNA profiling of 65 biopsies and 165 blood samples of a large cohort of renal transplant patients with precisely characterized pathologies. Immunoproteasome beta subunit 10 was found to be specifically increased in the graft and blood samples during chronic active antibody-mediated rejection and was also significantly increased in rat cardiac allografts undergoing acute rejection as well as chronic active antibody-mediated rejection. This syndrome is characterized by chronic transplant vasculopathy associated with diffuse C4d staining and circulating donor-specific antibodies. Using this animal model, we found that administration of the proteasome inhibitor, Bortezomib, delayed acute rejection and attenuated the humoral response in both the acute phase and established state of this syndrome in a dose-dependent manner. Following treatment with this reagent, donorspecific antibodies and C4d deposition were reduced. These studies highlight the role of the proteasome in chronic rejection and identify this molecule as a marker of this syndrome. Long-term graft loss remains the bane of kidney transplantation. More recently, much attention has been paid to the 'humoral' theory of chronic allograft rejection. 1 Evidence for the involvement of a humoral arm of the immune response to allografts has come from studies analyzing the impact of anti-human leukocyte antigen (HLA) antibodies on graft outcome, 2, 3 and evidence of complement cascade activation within kidney grafts diagnosed by intragraft deposition of the complement split product C4d. 4, 5 These data were recently reinforced when the definition of chronic active antibodymediated rejection (CAMR) was introduced into the Banff classification of kidney graft injury as an association of specific histological lesions associated with diffuse C4d deposition in peritubular capillaries and circulating donorspecific anti-HLA (DSA) antibodies. 6 Current therapies to combat the acute form of antibodymediated rejection aim to reduce antibody titers through the use of intravenous immunoglobulin, 7 plasmapheresis, 8 or B-cell-targeting antibodies such as Rituximab, 9 but these have not gained notoriety in the chronic form. Moreover, these strategies do not seem to have an effect on plasma cells, the source of antibodies. Thus, the development of more effective strategies would benefit patients suffering from this type of late graft rejection with such a poor prognosis. 10 The identification of molecular markers associated with CAMR would not only facilitate its diagnosis, but could also help to understand the pathophysiology of CAMR and thus aid in the design of new therapeutic strategies. Currently, CAMR diagnosis depends on the triad of graft lesions together with intragraft C4d and DSA mentioned above. Neither one of these alone can diagnose CAMR; DSA are predictive of graft loss but have not yet been shown to tightly correlate with intragraft lesions, and C4d has recently been shown to be absent in up to 50% of CAMR cases. 11 Here, using a gene-set comparison approach, we describe the identification of a well-known molecule, the immunoproteasome-b subunit 10 (PSMB10, also known as MECL-1) as a potential marker of CAMR in humans.
Moreover, we obtained concordant results in a rat heart allograft model that we have recently described as a pertinent model of CAMR (histological lesions of chronic vascular damage, persisting antidonor antibodies and diffuse C4d deposits on the graft vasculature). 12 Here we show that, in this model, inhibition of the proteasome significantly prolongs allograft survival by preventing acute rejection, and also attenuates established humoral immune responses (decreases DSA and C4d deposition) in both short-and long-term surviving recipients. Our data suggest the implication of the immunoproteasome in CAMR with PSMB10 as a potentially useful marker and point toward proteasome inhibition as a means of treating both acute rejection and CAMR.
RESULTS
Identification of the inducible member of the immunoproteasome, PSMB10, as a potential intragraft biomarker of chronic graft injury in human kidney transplantation
In order to identify potential diagnostic markers of chronic graft injury in humans, we compared several microarray data sets published in the literature in the context of human kidney transplant biopsies with chronic lesions (referred to as CAN or chronic rejection in the studies in question; Table 1 ). In total, less than 20 molecules were found to be common between at least two data sets (not shown). Among them, PSMB10 was found to be upregulated in chronic rejection in a study by Donauer et al. 13 and in Banff grade 3 versus Banff grade 0 in a study by Flechner et al.
14 PSMB10 was chosen from among the others because of its function as an instrumental member of the immunoproteasome and the availability of reagents to test it as a potential therapeutic target. In fact, the immunoproteasome was shown to be involved in antigen processing for presentation, 15 and proteasome inhibition was shown to blunt antibody responses in mice. 16 In healthy individuals, PSMB10 is expressed constitutively by the immune system (the spleen, peripheral blood, and lymph nodes; Supplementary Figure S1A ) and by lymphocytes and monocytes, where its expression is regulated by cell activation (Supplementary Figure S1A and B). It can also be induced through exposure to interferon-g.
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PSMB10 is upregulated in CAMR in human kidney transplant recipients
We analyzed PSMB10 in graft biopsies with different histological diagnoses ( Table 2) . As shown in Figure 1a , PSMB10 mRNA was specifically upregulated in biopsies with CAMR (Po0.001). Of note, PSMB10 expression was not correlated with proteinuria (r ¼ À0.16; P ¼ 0.63). Receiver operator characteristic (ROC) curve analysis revealed that PSMB10 mRNA had an excellent capacity to discriminate CAMR from the other histological diagnoses, with an area under the curve of 0.92 (Po0.0001, 95% confidence interval of 0.84-0.97). At a cut-off of 1.95, there was a sensitivity of 0.85 and a specificity of 0.83 (Figure 1b ). Thus, PSMB10 shows potential as an intragraft marker of CAMR in humans.
Given that ACR is becoming a rare phenomenon, we next focused on CAMR, to determine whether the specific regulation of PSMB10 was reflected in the peripheral blood. PSMB10 was analyzed in 150 kidney transplant recipients with stable graft function and 15 patients with CAMR ( Table 3) . As shown in Figure 2 , patients with CAMR had significantly higher levels of PSMB10 than those with stable graft function (Po0.01). Again, PSMB10 expression was not correlated with proteinuria (r ¼ À0.01; P ¼ 0.98).
To assess whether PSMB10 could potentially serve as a minimally invasive clinical decision-making tool, ROC curve analysis was performed. The results (Figure 2b) showed that this molecule analyzed in recipient blood could still discriminate CAMR from the other groups of patients well, albeit less than in the biopsies, with an area under the curve of 0.72 (Po0.01; 95% confidence interval of 0.57-0.84). At a cut-off of 0.96, there was a sensitivity of 0.67 and a specificity of 0.64.
Potential confounding factors influencing the expression of PSMB10
We next performed a multivariate analysis on the 150 stable patients to evaluate the potential impact of clinical and demographic factors on the expression of PSMB10 in the peripheral blood (Table 3) . Of all the parameters tested (legend to Figure 2 ), the statistically significant parameters identified as being associated with PSMB10 mRNA expression were recipient gender (Po0.05) and time posttransplant (Po0.01). Thus, creatinine clearance, proteinuria, donor and recipient age, number of HLA incompatibilities (A þ B þ DR), and maintenance immunosuppression were not confounders, neither were presence or absence of anti-HLA. Thus, PSMB10 is not simply a reflection of presence of anti-HLA antibodies. These data are modeled in Figure 2c , where predicted values of PSMB10 are expressed according to time post-transplant and recipient gender. PSMB10 was thus significantly higher in the peripheral blood mononuclear cells (PBMCs) of male recipients compared with female recipients (Po0.05) and displayed a distinctive inverse bell-shaped relationship with time post-transplant. However, these potentially confounding factors could not explain the difference in PSMB10 between stable (STA) and CAMR, because there was no difference in time post-transplant or recipient gender between the STA and CAMR groups (P ¼ not significant). Thus, overall these data show that PSMB10 may also be a peripheral blood biomarker of CAMR in humans, but some potential confounding factors may exist and need to be taken into consideration.
PSMB10 as an intragraft and peripheral blood marker of acute rejection as well as CAMR in a rat cardiac allograft model
To determine whether we could reproduce the above data in a rodent model, PSMB10 mRNA was analyzed in the grafts and PBMCs of rat recipients of cardiac allografts undergoing acute rejection or CAMR. We found that PSMB10 was significantly increased in the cardiac allografts during both acute rejection (at day (D)7 post-transplant) and CAMR (analyzed at D100 post-transplant) compared with syngeneic controls (Figure 3a ; Po0.01 and Po0.0001, respectively). A different expression profile was observed in the PBMCs, where PSMB10 displayed no change during acute rejection, suggesting an effect of DST priming on PBMCs. Moreover, similar to in humans, a significant increase was observed during CAMR at D100 post-transplant (Figure 3b ; Po0.05). Thus, PSMB10 shows potential as an intragraft and peripheral blood marker of CAMR in rats and humans.
The proteasome as a therapeutic target for AR: prolonged survival and attenuation of the humoral response during AR in a rat cardiac allograft model upon immunoproteasome inhibition with Bortezomib
Given this upregulation of PSMB10 in acute rejection and CAMR in this rodent model, we set out to determine whether proteasome inhibition could influence graft outcome. In the context of acute rejection, recipients of major histocompatibility complex (MHC)-mismatched cardiac allografts were treated with Bortezomib every other day from D0-D20. The data presented in Figure 4a show that Bortezomib dosedependently prolonged cardiac allograft survival with an optimal effect at 0.1 mg/kg, giving a mean survival of 31.7 days (n ¼ 6) (versus 6.3 days in untreated controls (n ¼ 4); Po0.01). Moreover, at D7, there were significantly lower circulating anti-donor MHC class I and II antibodies for total immunoglobulin G (IgG) (Po0.01) as well as IgG1 (Po0.01), and IgG2c (Po0.05), with no reduction for IgG2a or IgG2b (Figure 4b ).
The proteasome as a therapeutic target for CAMR: attenuation of the humoral response during CAMR in a rat cardiac allograft model upon immunoproteasome inhibition with Bortezomib
In the context of CAMR, Bortezomib was initially administered every other day from D80 to D100 at 0.1 mg/kg in rat recipients of cardiac allografts that had received DST before transplantation and were surviving long-term. The DST þ Bortezomib recipients had significantly reduced levels of circulating anti-donor MHC class I and II antibodies for total IgG as well as IgG1, IgG2a, IgG2b, and IgG2c ( Figure 5a ). Bortezomib-treated recipients tended to display less intra-graft complement deposition (Table 4 ). In fact, although the grafts of DST-treated animals displayed diffuse linear expression of C4d (Figure 5b , left-hand panel and magnified insert), two Bortezomib-treated animals showed only vague background staining, whereas the others displayed minimal staining (Figure 5b , right-hand panel and magnified insert). There were no differences between the two groups in terms of infiltrate, fibrosis, vascular obstruction, vascular lesions, and number of affected arteries; however, myocyte necrosis was absent in four of the five animals in the Bortezomib-treated group (Table 4 and examples in Figure  5c , far left and middle panels). We thus performed further experiments in which treatment was initiated earlier at D60 and continued until D100. Again, a significant decrease in circulating anti-donor MHC class I and II antibodies for total IgG as well as for three of the four IgG subtypes tested was noted at D100 post-transplant in the Bortezomib-treated recipients (Figure 5d ). This decrease was not simply a timedependent effect. because recipients had significantly less DSA after the 40-day treatment versus before treatment, whereas DSA levels were unchanged in untreated animals over the same time period (Figure 5e ). C4d staining at D100 in this group was heterogeneous (Table 4) . A histological analysis at D100 showed that there was a tendency toward reduced vascular lesions and a significant reduction in fibrosis compared with the untreated DST group (Po0.05; Table 4 and an example Figure 5c , far right panel). Thus, in this model and at the dose and schedules studied, Bortezomib is able to significantly attenuate the humoral immune response in graft recipients undergoing CAMR with a reduction in fibrosis and a tendency to reduce the histological lesions of transplant vasculopathy. Finally, as PSMB10 expression did not correlate with proteinuria in the blood or graft of humans, we wished to confirm this in a rat model. For this purpose, we analyzed PSMB10 in Buffalo/Mna rats, a well-known rat model of proteinuria due to spontaneous idiopathic nephritic syndrome of unknown origin (see Materials and Methods Results represent pooled data for 6-month protocol biopsies and biopsies taken at X1-year post-transplantation (similar results were found for the two cohorts). Statistical significance according to a Kruskal-Wallis test followed by a Dunn's Multiple Comparison test is indicated: ***Po0.001. PSMB10 mRNA was measured by quantitative PCR using a TaqMan probe set (Hs00160620_m1). Expression levels were calculated using the 2ÀDDC t method where the reference represents onefold expression, as previously described. 44 Hypoxanthine phosphoribosyl transferase (Hs99999909_m1) was used as an endogenous control to normalize RNA starting quantity. (b) Receiver operator characteristic (ROC) curve analysis of PSMB10 in the combined 6-month and X1-year biopsy cohorts; its capacity to discriminate CAMR from all the other biopsies is analyzed. The DSAs were directed against class II (n=11), class I (n=1), or both (n=3).
Kidney International (2010) 77, 880-890 section for details). As shown in the Figure 6 , PSMB10 was not significantly differentially expressed between rats with or without proteinuria, despite radical differences in proteinuria.
DISCUSSION
Here we used a literature gene-set comparison approach and identified PSMB10 as a potential biomarker of chronic graft injury. Further profiling by quantitative PCR in biopsies and PBMCs of renal transplant recipients revealed this molecule to be specifically increased in the graft and blood in CAMR. PSMB10 was also significantly increased in rat cardiac allograft models with acute or chronic rejection. In the acute model, administration of the proteasome inhibitor Bortezomib not only dose-dependently delayed acute rejection but also attenuated the humoral response. In the chronic model with established CAMR, Bortezomib treatment decreased DSA and C4d deposition and improved some aspects of the chronic tissue injury. These data thus suggest PSMB10 as a potential marker and the proteasome as a therapeutic target for CAMR.
Proteasomes are large protease complexes located in cytoplasm and nuclei that degrade cellular proteins in a ubiquitin-dependent and adenosine triphosphate-dependent manner present in immune cells. 18 In response to interferon-g, the three catalytic subunits are replaced by their homologous subunits, PSMB 8, 9, and 10, to form the so-called immunoproteasome, which is essential for processing antigenic peptides for presentation through the class I MHC complex. 15 Immunoproteasomes have additional effects that are independent to class I processing, for example, they inhibit T-cell proliferation, as T cells lacking immunoproteasome subunits hyperproliferate in vitro and in vivo, and KO mice have higher numbers of central memory CD8 þ cells. 19 Experiments in KO mice have revealed that PSMB10 is involved in controlling homeostatic equilibrium between T-cell subsets, 20 thereby controlling the T-cell repertoire. 21 Given the expression of PSMB10 by lymphocytes and monocytes, it is possible that the increase in PSMB10 in the graft in CAMR may be the result of specific infiltration of these cells. B cells in particular may be involved in this because patients with chronic rejection undergo lymphoid neogenesis with the development of intragraft B-cell germinal centers. 22 Likewise, increased PSMB10 expression may come from locally present activated monocytes or mature dendritic cells, as the immunoproteasome is known to be increased in these cells. 23 Given that the proteasome decreases during late phase plasma cell differentiation, 24 it is unlikely that the increase in PSMB10 in the peripheral blood stems from an increase in plasma cells in chronic rejection. ROC curve analysis suggested that the level of PSMB10 in the blood of graft recipients could be useful to diagnose CAMR, although it may not be sufficient as a stand-alone marker and could be combined with other markers to improve its diagnostic performance. Moreover, we found PSMB10 levels to be influenced by recipient gender and time post-transplant (but not presence of anti-HLA or renal function), highlighting the need to take confounding factors into account in biomarker analyses. Thus, PSMB10 is not simply a reflection of DSA or poor renal function, but rather of histological lesions together with C4d and DSA. Future analyses on simultaneous biopsy blood samples, which were not possible here because of lack of material, could be considered to directly compare intragraft and peripheral blood diagnostic performance.
The intragraft upregulation of PSMB10 we observed in CAMR in both humans and rats prompted us to test the proteasome inhibitor Bortezomib in the rat models of both acute rejection and CAMR. Currently, Bortezomib is used in the clinic for multiple myeloma and solid tumors. 25 However, a limited number of studies have analyzed the effect of this drug on acute rejection in murine models of transplantation, showing a preventative effect on both heart 26 and islet 27 allograft acute rejection. On the basis of blood biochemistry, Bortezomib was also associated with side effects, but these were reversible upon cessation of treatment. 27 Our data in a rat model of acute heart rejection are similar to those reported in the mouse, with a similar survival prolongation observed in both models. In the chronic model, diminution of some aspects of chronic injury was observed. The preventative effect on acute rejection is compatible with the hypothesis that proteasome inhibition reduces alloantigenicity by reducing class I presentation. Moreover, we observed a significant decrease in antibody production, suggesting an attenuating effect on the humoral response. Very recent data showed that proteasome inhibition specifically induces death of activated T cells, 28 and suppresses essential immune function of CD4 þ T cells upon activation by allogeneic dendritic cells. 29 Moreover, proteasome inhibition has been shown to modulate toll-like receptor4-induced dendritic cell activation, 30 which could have a role here, as we recently found toll-like receptor 4 to be increased in the graft and blood of CAMR patients. 31 We also found that in a rat model of CAMR, Bortezomib decreased the humoral immune response by significantly reducing DSA. These data are in accordance with a recent report that proteasome inhibition blunts Ab responses following in vivo B-cell activation in mice, by promoting apoptosis. 16 In the latter study, immunoproteasome subcomponents decreased during B-cell differentiation, in parallel with increased immunoglobulin synthesis. More recently, Bortezomib was shown to rapidly and efficiently deplete both short-and long-lived plasma cells in the spleens and bone marrow in a murine model of lupus-like disease, leading to reduced autoantibody development. 32 Moreover, Bortezomib has recently been shown to induce apoptosis of plasma cells, to block anti-HLA Ab secretion in vitro, and to transiently decrease plasma cells in vivo in renal transplant recipients. 33, 34 However, in the latter studies in humans, Bortezomib was used in combination with other immunosuppressors and plasma exchange making it difficult to pinpoint the specific role of Bortezomib among the treatment arsenal. Moreover, its effect on graft histology has yet to be determined. In our model, we show a clear-cut effect of Bortezomib monotherapy on DSA and C4d, significantly reduced allograft fibrosis and a tendency toward reduced vascular lesions. Therefore, early treatment with Bortezomib may be pivotal to prevent irreversible chronic lesions. Further analyses in a rodent model of kidney transplantation would also be interesting, although for the moment there are no true models of CAMR in the kidney. Indeed, in the Fischer to Lewis kidney transplant model of chronic allograft nephropathy (reviewed by Marco 35 ), our own experience revealed chronic pyelonephritis with no vascular lesions (data not shown).
On the whole, our data point toward PSMB10 as a potentially useful intragraft and peripheral blood marker for CAMR, with immunoproteasome inhibition as a valuable treatment strategy for antibody-mediated rejection.
MATERIALS AND METHODS Gene-set comparison
With the aim of identifying relevant biomarkers of late graft injury, we compared the gene sets from four microarray studies of late kidney graft injury published in the literature 13, 14, 36, 37 (see Table 1 ). To overcome the problem of a single gene having numerous denominations, accession numbers, and so on, all genes were converted into a single common identifier, the 'gene ID,' using the gene ID conversion tool available on the DAVID Bioinformatic Resources 2006 website (http://www.david.abcc.ncifcrf.gov/ home.jsp). Gene IDs from the different studies representing were sorted in Microsoft Excel and repeats of the same ID identified.
Human kidney transplant recipients
Study groups. All patients who participated in this study gave informed consent, and the study was approved by the University Hospital Ethical Committee and the Committee for the Protection of Patients from Biological Risks. The study was performed on 65 biopsies and 165 blood samples. Samples were included prospectively on the basis of histological or clinical criteria. (a) Biopsies were collected at two centers, Nantes, France (n ¼ 45) and Hanover, Germany (n ¼ 20). Of the total 65 biopsies, 29 were protocol biopsies at 6 months or 1 year and the remaining 36 were biopsies for cause. All were classified according to the updated Banff classification criteria, 6 as displaying normal histology (N-C4d-negative and DSA-negative; n ¼ 13) or lesions of interstitial fibrosis and tubular atrophy of unknown etiology (IF/TA-C4d-negative and DSA-negative; n ¼ 16) or lesions of calcineurin inhibitor toxicity (tox-C4d-negative and DSA-negative; n ¼ 14), or lesions of acute cellular rejection (ACR; n ¼ 9) or CAMR (defined by the presence of circulating DSA associated with transplant glomerulopathy and deposition of C4d in peritubular capillaries (n ¼ 13). C4d staining was performed on frozen sections with 450% staining being considered as positive. The demographic and clinical data for all of these patients are provided in Table 2 . (b) Peripheral blood mononuclear cells (PBMCs) were prepared from the blood of 165 kidney transplant patients (largely independent from those included in the biopsy analysis) whose statuses were defined on a histological and/or clinical basis: Stable graft function (patients under standard immunosuppression with stable graft function (creatinemia o150 mmol/l and proteinuria o1 g/24 h for at least 3 years including over the two previous 6-month follow-up appointments with o20% change between the two time points: STA; n ¼ 150), or CAMR as defined above (n ¼ 15). The demographic and clinical data for these patients are provided in Table 3 .
Rodent transplant models
Study groups. Inbred male adult rats (200-250 g) of the LEW.1A (RT1a) and LEW.1W (RT1u) MHC-incompatible congeneic strains were purchased from Janvier (Le GenestSaint-Isle, France) and maintained in an animal facility under standard conditions according to the European and Institutional Guidelines. (a) Acute rejection of heart allografts. LEW.1A rats received heterotopic heart allografts from LEW.1W donors as previously described 38 and received no immunosuppressive treatment. Rejection (cessation of heart beating assessed by daily abdominal palpation) occurs at a mean of 6.3 days post-transplant. (b) Chronic antibody-mediated rejection of heart allografts.
LEW.1A rat recipients were transfused intravenously with 1 ml of blood from a LEW.1W donor 14 and 7 days before heterotopic LEW.1W cardiac transplantation as described. 39 Graft function was evaluated as above. In this strain combination, donor-specific transfusion induces long-term graft survival but does not inhibit the indirect pathway of allorecognition, resulting in histological lesions of chronic transplant vasculopathy 40 associated with deposition of the complement split product C4d and circulating DSAs. induced long-term allograft survival. Heart allograft recipients were treated with DST as described above and received Bortezomib intraperitoneally at 0.1 mg/kg every other day either from D80 until D100 or from D60 until D100. At this time, all allografts present vascular lesions with diffuse C4d deposits and circulating anti-DSA.
Rodent proteinuria model
The Buffalo/Mna rat strain maintained in our laboratory was provided by Dr Saito (Central Experimental Institute, Nokawa, Kawasaki, Japan). These rats have spontaneous idiopathic nephritic syndrome of unknown origin as previously described. 41 They do not have proteinuria at 1 month of age but develop significant proteinuria by 6 months of age. Animal care was in accordance with our institutional guidelines. The rats were placed in metabolic cages for 24 h and total urinary protein concentration (g/l) was measured by a colorimetric method using a Hitachi autoanalyzer (Boehringer, Reims, France). Proteinuria was expressed according to the formula proteinuria (g/mmol) ¼ urinary proteins (g/l)/urinary creatinine (mmol/l), and it was considered to be abnormal at values 40.2 g/mmol.
Sample preparation
Human kidney transplant biopsies were processed as described. 42 Rat heart transplant or kidney tissue was processed as described. 40 Human and rat peripheral blood was collected in EDTA vacutainers and PBMCs separated by density centrifugation using Lymphosep, lymphocyte separation media (Bio West, Nuaille, France). PBMCs were stored in TRIzol (Invitrogen, Cergy Pontoise, France) at À801C until use.
RNA extraction and reverse transcription. Human biopsies were processed as described in detail. 42 Rat heart allografts and rat and human PBMCs were processed using the TRIzol method (Invitrogen) according to the manufacturer's instructions. RNA quality and quantity was determined using an Agilent 2100 BioAnalyzer (Palo Alto, CA, USA). Genomic DNA was removed by DNase treatment (Roche, Indianapolis, IN, USA). RNA was reverse transcribed into cDNA using polydT oligonucleotide and Maloney leukemia virus reverse transcription (Invitrogen).
Real-time quantitative PCR. Real-time quantitative PCR was performed in an Applied Biosystems GenAmp 7700 sequence detection system (Applied Biosystems, Foster City, CA, USA) as described in detail, 42 using commercially available primer and probe sets (Applied Biosystems).
Rat cardiac allograft histological analyses and C4d immunostaining. Heart allografts were prepared as described by Ballet et al. 12 and analyzed by a pathologist (KR) (see also Table 4 and legend). C4d deposition was localized as described by Ballet et al. 12 using an affinity-purified polyclonal rabbit antibody to C4d kindly provided by Baldwin and group 43 (department of pathology, John Hopkins Medical Institutions, Baltimore, MD, USA).
Measurement of circulating anti-donor antibodies in rat recipients of cardiac allografts. Anti-donor class I and II total IgG and subtypes in the sera of untreated or Bortezomibtreated recipients at D7 post-transplantation, and in DSTtreated and DST þ Bortezomib-treated animals at D60 and D100 post-transplantation were measured as described by Ballet et al.
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Statistical analyses
The non-parametric Mann-Whitney test was used for comparison between two groups. Note that there was an imbalance in sample size between the CAMR and STA patients (n ¼ 15 versus 150); this was because we preferred to use all available STA samples to better reflect the relatively low prevalence of CAMR and to use all samples that were used for the other analyses (multivariate analyses and ROC). Such an imbalance is authorized within the context of the non-parametric Mann-Whitney test. The non-parametric Kruskal-Wallis test was performed for comparison of three or more groups, followed by Dunn's multiple comparisons test. ROC curve analysis was performed to determine the cut-off point of PSMB10 in biopsies and/or blood that yielded the highest combined sensitivity and specificity in diagnosing CAMR (see Figure 1 legend for explanation). Note that the n ¼ 15 CAMR were compared with a large number of STA patients (n ¼ 150) in order to better reflect the relatively low prevalence of CAMR in this diagnostic test. The effect of the different clinical and demographic parameters on the expression of PSMB10 in patients with stable graft function, a multivariate linear regression analysis, was performed following log transformation of the data taking into account the various parameters (see legend to Figure 2 ). The statistical software used was GraphPad prism 5.
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